The primary resistance of Helicobacter pylori in Taiwan after the national policy to restrict antibiotic consumption and its relation to virulence factors - A nationwide study

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Liou, Jyh Ming ^a   Chang, Chi Yang ^b   Chen, Mei Jyh ^a   Chen, Chieh Chang ^a   Fang, Yu Jen ^a   Lee, Ji Yuh ^a   Wu, Jeng Yih ^c   Luo, Jiing Chyuan ^d   Liou, Tai Cherng ^e   Chang, Wen Hsiung ^e   Tseng, Cheng Hao ^b   Wu, Chun Ying ^d,f   Yang, Tsung Hua ^a   Chang, Chun Chao ^g   Wang, Hsiu Po ^a   Sheu, Bor Shyang ^h   Lin, Jaw Town ⁱ   Bair, Ming Jong ^e,j   Wu, Ming Shiang ^a   Tai, Chi Ming ^b   Lee, Ching Tai ^b   Wang, Wen Lun ^b   Lee, Yi Chia ^a   Wang, Yu Chi ^b   Taiwan Gastrointestinal Disease and Helicobacter Consortium, ^k   more..

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b I SHOU UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e MACKAY MEMORIAL HOSPITAL   (Taiwan)

^f TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^g TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^h NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

ⁱ FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^j MEIHO UNIVERSITY   (Taiwan)

^k Department of Nursing Meiho University ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; LEVOFLOXACIN; METRONIDAZOLE; NITROIMIDAZOLE; TETRACYCLINE; VIRULENCE FACTOR; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATION; CAGA GENE; CONTROLLED STUDY; DRUG USE; ERADICATION THERAPY; FEMALE; GENE; GENOTYPE; HEALTH CARE POLICY; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; SEX DIFFERENCE; TAIWAN; VACA GENE; DRUG EFFECTS; GENETICS; GROWTH, DEVELOPMENT AND AGING; HELICOBACTER INFECTIONS;

HELICOBACTER PYLORI;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; FEMALE; GENOTYPE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; TAIWAN; TETRACYCLINE; VIRULENCE FACTORS;

EID: 84929096058     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0124199     Document Type: Article

References (33)

1. Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013; 62:34-42. doi: 10.1136/gutjnl-2012-302254 PMID: 22580412
2. Camargo MC, García A, Riquelme A, Otero W, Camargo CA, Hernandez-García T, et al. The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America. Am J Gastroenterol. 2014; 109:485-495. doi: 10.1038/ajg.2014.24 PMID: 24589670
3. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, et al. Management of Helicobacter pylori infection - the Maastricht IV/ Florence Consensus Report. Gut. 2012; 61: 646-664. doi: 10.1136/gutjnl-2012-302084 PMID: 22491499
4. Vakil N, Megraud F. Eradication therapy for Helicobacter pylori. Gastroenterology. 2007; 133: 985-1001. PMID: 17854602
5. Chang SC, Chen YC, Hu OY. Antibiotic use in public hospitals in Taiwan after the implementation of National Health Insurance. J Formos Med Assoc. 2001; 100:155-161. PMID: 11393108
6. Ho M, Hsiung CA, Yu HT, Chi CL, Chang HJ. Changes before and after a policy to restrict antimicrobial usage in upper respiratory infections in Taiwan. Int J Antimicrob Agents. 2004; 23:438-445. PMID: 15120720
7. Khan A, Farooqui A, Manzoor H, Akhtar SS, Quraishy MS, Kazmi SU. Antibiotic resistance and CagA gene correlation: a looming crisis of Helicobacter pylori. World J Gastroenterol. 2012; 18:2245-2252. doi: 10.3748/wjg.v18.i18.2245 PMID: 22611319
8. Taneike I, Nami A, O'Connor A, Fitzgerald N, Murphy P, Qasim A, et al. Analysis of drug resistance and virulence-factor genotype of Irish Helicobacter pylori strains: is there any relationship between resistance to metronidazole and cagA status? Aliment Pharmacol Ther. 2009; 30:784-790. doi: 10.1111/j.1365-2036.2009.04095.x PMID: 19604178
9. De Francesco V, Margiotta M, Zullo A, Hassan C, Valle ND, Burattini O, et al. Claritromycin resistance and Helicobacter pylori genotypes in Italy. J Microbiol. 2006; 44:660-664. PMID: 17205045
10. Liou JM, Lin JT, Chang CY, Chen MJ, Cheng TY, Lee YC, et al. Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design. Gut. 2010; 59: 572-578. doi: 10.1136/gut.2009.198309 PMID: 20427390
11. Liou JM, Chen CC, Chen MJ, Chen CC, Chang CY, Fang YJ, et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet. 2013; 381:205-213. doi: 10.1016/S0140-6736(12)61579-7 PMID: 23158886
12. Hung KH, Sheu BS, Chang WL, Wu HM, Liu CC, Wu JJ. Prevalence of primary fluoroquinolone resistance among clinical isolates of Helicobacter pylori at a University Hospital in Southern Taiwan. Helicobacter. 2009; 14:61-65. doi: 10.1111/j.1523-5378.2009.00655.x PMID: 19191898
13. Poon SK, Chang CS, Su J, Lai CH, Yang CC, Chen GH, et al. Primary resistance to antibiotics and its clinical impact on the efficacy of Helicobacter pylori lansoprazole-based triple therapies. Aliment Pharmacol Ther. 2002; 16:291-296. PMID: 11860412
14. Huang AH, Sheu BS, Yang HB, Huang CC, Wu JJ, Lin XZ. Impact of Helicobacter pylori antimicrobial resistance on the outcome of 1-week lansoprazole-based triple therapy. J Formos Med Assoc. 2000; 99:704-709. PMID: 11000734
15. National Health Insurance Research Database; 2005. Data subsets: Longitudinal Health Insurance Database (LHID) [Internet]. Available: http://nhird.nhri.org.tw/en/Data-Subsets.html#S3.
16. Huang LY, Shau WY, Chen HC, Su S, Yang MC, Yeh HL, et al. Pattern analysis and variations in the utilization of antihypertensive drugs in Taiwan: a six-year study. Eur Rev Med Pharmacol Sci. 2013; 17:410-419. PMID: 23426547
17. Liou JM, Chen CC, Chang CY, Chen MJ, Fang YJ, Lee JY, et al. Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial. J Antimicrob Chemother. 2013; 68:450-456. doi: 10.1093/jac/dks407 PMID: 23099849
18. Vilaichone RK, Yamaoka Y, Shiota S, Ratanachu-ek T, Tshering L, Uchida T, et al. Antibiotics resistance rate of Helicobacter pylori in Bhutan. World J Gastroenterol. 2013; 19:5508-5512. doi: 10.3748/wjg.v19.i33.5508 PMID: 24023494
19. Su P, Li Y, Li H, Zhang J, Lin L, Wang Q, et al. Antibiotic resistance of Helicobacter pylori isolated in the Southeast Coastal Region of China. Helicobacter. 2013; 18:274-279. doi: 10.1111/hel.12046 PMID: 23418857
20. Gao W, Cheng H, Hu F, Li J, Wang L, Yang G, et al. The evolution of Helicobacter pylori antibiotics resistance over 10 years in Beijing, China. Helicobacter. 2010; 15:460-466. doi: 10.1111/j.1523-5378.2010.00788.x PMID: 21083752
21. Sun QJ, Liang X, Zheng Q, Gu WQ, Liu WZ, Xiao SD, et al. Resistance of Helicobacter pylori to antibiotics from 2000 to 2009 in Shanghai. World J Gastroenterol. 2010; 16:5118-5121. PMID: 20976850
22. Lee JW, Kim N, Kim JM, Nam RH, Chang H, Kim JY, et al. Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter. 2013; 18:206-214. doi: 10.1111/hel.12031 PMID: 23241101
23. Okamura T, Suga T, Nagaya T, Arakura N, Matsumoto T, Nakayama Y, et al. Antimicrobial resistance and characteristics of eradication therapy of Helicobacter pylori in Japan: a multi-generational comparison. Helicobacter. 2014; 19:214-220. doi: 10.1111/hel.12124 PMID: 24758533
24. Vilaichone RK, Gumnarai P, Ratanachu-Ek T, Mahachai V. Nationwide survey of Helicobacter pylori antibiotic resistance in Thailand. Diagn Microbiol Infect Dis. 2013; 77:346-349. doi: 10.1016/j.diagmicrobio.2013.08.010 PMID: 24094837
25. Binh TT, Shiota S, Nguyen LT, Ho DD, Hoang HH, Ta L, et al. The incidence of primary antibiotic resistance of Helicobacter pylori in Vietnam. J Clin Gastroenterol. 2013; 47:233-238. doi: 10.1097/MCG.0b013e3182676e2b PMID: 23090037
26. Perez Aldana L, Kato M, Nakagawa S, Kawarasaki M, Nagasako T, Mizushima T, et al. The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance. Helicobacter. 2002; 7:306-309. PMID: 12390210
27. Kupcinskas L, Rasmussen L, Jonaitis L, Kiudelis G, Jørgensen M, Urbonaviciene N, et al. Evolution of Helicobacter pylori susceptibility to antibiotics during a 10-year period in Lithuania. APMIS. 2013; 121:431-436. doi: 10.1111/apm.12012 PMID: 23078193
28. Lõivukene K, Maaroos HI, Kolk H, Kull I, Labotkin K, Mikelsaar M. Prevalence of antibiotic resistance of Helicobacter pylori isolates in Estonia during 1995-2000 in comparison to the consumption of antibiotics used in treatment regimens. Clin Microbiol Infect. 2002; 8:598-603. PMID: 12427220
29. Kostamo P, Veijola L, Oksanen A, Sarna S, Rautelin H. Recent trends in primary antimicrobial resistance of Helicobacter pylori in Finland. Int J Antimicrob Agents. 2011; 37:22-25. doi: 10.1016/j.ijantimicag.2010.09.013 PMID: 21084175
30. Miendje Deyi VY, Bontems P, Vanderpas J, Vanderpas J, De Koster E, Ntounda R, et al. Multicenter survey of routine determinations of resistance of Helicobacter pylori to antimicrobials over the last 20 years (1990 to 2009) in Belgium. J Clin Microbiol. 2011; 49:2200-2209. doi: 10.1128/JCM.02642-10 PMID: 21450969
31. Wueppenhorst N, Stueger HP, Kist M, Glocker EO. High secondary resistance to quinolones in German Helicobacter pylori clinical isolates. J Antimicrob Chemother. 2013; 68:1562-1566. doi: 10.1093/jac/dkt061 PMID: 23463210
32. Niederman MS. Review of treatment guidelines for community-acquired pneumonia. Am J Med. 2004; 117 (Suppl 3A):51S-57S. PMID: 15360097
33. Shiota S, Suzuki R, Yamaoka Y. The significance of virulence factors in Helicobacter pylori. J Dig Dis. 2013; 14:341-349. doi: 10.1111/1751-2980.12054 PMID: 23452293